Sysmex (OTCMKTS:SSMXY) Updates FY 2026 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) updated its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.382-0.382 for the period, compared to the consensus EPS estimate of 0.440. The company issued revenue guidance of $3.4 billion-$3.4 billion, compared to the consensus revenue estimate of $3.1 billion.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered shares of Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Sysmex currently has a consensus rating of “Hold”.

Sysmex Stock Up 0.6%

Shares of OTCMKTS:SSMXY opened at $10.30 on Friday. The company has a quick ratio of 2.46, a current ratio of 3.26 and a debt-to-equity ratio of 0.12. The business’s 50 day moving average is $9.34 and its 200 day moving average is $9.06. The stock has a market cap of $6.48 billion, a P/E ratio of 27.11 and a beta of 1.05. Sysmex has a 52-week low of $8.01 and a 52-week high of $14.24.

Sysmex (OTCMKTS:SSMXY) last released its quarterly earnings data on Friday, August 7th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.02. Sysmex had a net margin of 7.13% and a return on equity of 7.23%. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Sell-side analysts predict that Sysmex will post 0.42 EPS for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.